

# Index

---

- Abbott, A. 131, 136, 168, 195
- adverse drug reaction (ADR) 41, 49  
reporting systems 54, 57, 67, 87, 91  
reports 7, 53, 59, 82, 91, 98, 156  
side-effects 5, 8, 12, 13, 16, 17, 37,  
82, 83, 89, 91, 99, 107, 139, 142,  
143, 148, 152, 153, 170, 183,  
194, 195, 197, 203  
signal of 12, 38, 43, 67, 73, 75, 77,  
82, 85, 87, 95, 154, 180, 181  
spontaneous notification 55, 56, 86,  
87, 90, 91, 108, 173, 194, 207
- Agence Française de Sécurité Sanitaire  
des Produits de Santé (AFSSAPS)  
83, 85
- American Medical Association (AMA)  
67
- Bauman, Howard 114, 124–6, 131–2,  
135
- Bayer 84, 85, 94
- Ben-David, J. 25
- boundary-organisations 34
- Bovine Spongiform Encephalopathy  
(BSE) 39, 44, 45, 46, 47, 70, 73,  
165, 166
- Boyle, Robert 29, 32, 208
- Braithwaite, J. and Drahos, P. 8, 20
- Brunsson, N. 10, 18, 33
- Cambrosio, A. 214
- Carpenter, D. 17, 73
- Cerivastatin 84–6, 92–8, 106, 153, 194,  
196, 205; *see also* Lipobay
- Chipping Campden 129
- circulation  
as defining experts 32  
as professional mobility 29  
between activities of control 33  
between evaluation and standard-  
setting 33
- invisibility of 11  
measurement of 28  
multi-professionalism and 169–71  
of drug safety experts 78, 99, 102,  
107  
of HACCP experts 119, 137,  
139–40  
of PMM experts 159, 161  
transnationalisation and 177–81
- clinical pharmacology  
as evaluative science 12, 37  
as experimental science 48–50; *see also* clinical trials  
co-word analysis of 57–8  
dose-response assessment and 48,  
57, 58  
drug regulation in the USA and  
66–7  
efficacy 48–50, 54, 58, 66, 67, 211,  
212  
history of 74  
pharmacovigilance and 53  
statistics and 56
- clinical trials; *see also* marketing  
authorisation  
as experiment 48–50  
as tool of qualification 37  
clinical pharmacology and 74  
for functional or novel foods 143  
generalisation of 41  
limits of 53–9, 77, 90, 98  
safety data from 14, 102, 106
- Codex Alimentarius (Codex)  
as receptacle of expert work  
125–30  
as standard setting organisation 33  
as WTO reference body 75  
Codex Committee on Food Hygiene  
128, 129  
Codex principles for risk analysis  
and EU food law 70

- consensus on HACCP and 134–40
- International guideline for HACCP 14, 112–22
- members of ICMSF and 132
- risk assessment and 69
- setting of critical control points and 129–30
- Committee for Proprietary Medicinal Products (CPMP) 41, 73, 88, 178; *see also* Committee for Human Medicinal Products (CHMP)
- Committee for the Safety of Drugs (CSD) 67
- Conference for the International Organization of Medical Sciences (CIOMS) 98, 101, 102–5, 108–9, 167, 177, 178, 181–3, 186–7, 193, 207; *see also* International Conference on Harmonisation (ICH)
- consensus
  - consensus conferences 15, 169
  - consensus, manufacturing of 11, 34, 134, 135, 137, 187
- conventional foods 144, 145, 151, 212
- Council of Ministers of the European Union 46
- co-word analysis 57, 61, 63, 213, 214
- Crane, D. 29–31, 34
- Crestor 153
  
- Daemmrich, A. 73
- development safety update report (DSUR) 102
- Directorate General XXIV 74; *see also* Directorate General for Health and Consumer Protection
- Directorate General for Health and Consumer Protection (DG SANCO) 45, 70, 161; *see also* DG XXIV
- Djelic, M.-L. and Sahlin-Andersson K. (eds.) 9
  
- drug safety
  - CIOMS and ICH 178, 182, 183
  - clinical pharmacology and 53
  - clinical trials and 56–9
  - drug safety and PVP 78–83
  - drug safety experts 14, 86, 89, 92–4, 98, 99, 102, 107–9, 173, 193, 196–7, 201, 202, 205
  - scientists' conception of 66
  - Drug Safety Research Unit (DSRU) 86
  - drug withdrawal
    - as result of pharmacovigilance activities 72
    - Cerivastatin 84–6, 88; *see also* Lipobay
    - periodic safety update report and 196
    - PVP and avoidance of 12
    - risk management and 94–7
    - series of 77–8
    - worldwide withdrawals of Vioxx and Lipobay 43
  - due diligence 123, 138
  
- European Commission
  - as international policy-making organisation 33
  - CIOMS and 182
  - European Medicines Evaluation Agency and 67
  - HACCP and 113, 118–22, 128, 137, 143
  - New Approach 118, 119, 128
  - Novel foods and 146, 147, 150, 153, 155, 161, 165
  - Elixir Sulfanilamide 39, 91
  - European Medicines Evaluation Agency (EMA); *see also* regulatory agencies
  - creation of 41
  - Gabriel and meetings at 177
  - globalisation of pharmaceutical regulation and 209
  - marketing authorisation decisions 195
  - pharmacovigilance missions 43
  - risk management guidelines 78, 80, 83, 84, 193, 195
  - risk management strategy 95–6
  - Environmental Protection Agency (EPA) 16, 64
  - European Medicines Agency (EMA): *see* European Medicines Evaluation Agency (EMA)

- epidemiology
  - combination with toxicology 64
  - detection of regularities 54
  - epidemiological surveillance 7, 47, 69, 72, 209
  - epidemiology-surveillance 12
  - imputation and 62
  - pharmacoepidemiology and 196
  - post-marketing surveillance and 68
  - safety specification and 80
- epistemic community 11, 19–21, 24–6, 28, 35–6, 189
- EudraVigilance 96
- European Federation of Pharmaceutical Industries and Associations (EFPIA) 102, 178
- European food law 43–7, 64, 70, 119, 121, 128, 144
- European Food Safety Authority (EFSA); *see also* regulatory agencies
  - coordination of surveillance plans 60
  - creation of 47
  - data collection mission 47
  - International Life Science Institute and 161, 206
  - members of EFSA panels 159, 160, 178
  - production of risk assessment opinions 47
  - recommendation on post-market monitoring studies 150
- European official guidelines on pharmacovigilance for medicinal products for human use (the ‘Volume 9’) 80
- European Parliament 45, 46, 47, 73, 74, 94, 146, 165
- European Pharmacovigilance Working Party (PHVWP) 43, 67, 73, 86, 101, 105, 107
- evaluation
  - as science 12, 15, 32, 35, 37, 38, 48, 169, 173, 183
  - regulation 196, 208
  - standard-setting and 11, 99, 108
- Evans, Stephen 86, 87, 88, 89, 90, 93, 98, 99; *see also* Waller, Patrick
- Expert; *see also* scientists
  - cooptation 76, 125, 135, 174, 183
  - hybridisation of expertise 197
  - industry advice 33, 132, 139, 187
  - label of expert 171, 188
  - prestige 20
  - quasi-regulators 107, 108, 188
  - recruitment 131, 134, 135, 158, 182
  - scientific advice 4, 36, 44, 45, 73, 167, 168, 174, 175, 180, 189
  - occupationalisation of 174
  - transnationalisation of experts’ career 177, 181, 188
- Federal Food Drug and Cosmetic Act 39
- Fischer, F. 206
- Food and Agricultural Organization (FAO) 70, 113, 131, 132, 135, 151, 159, 178
- Food and Chemical Toxicology* (FCT) 142, 143, 147, 149, 155
- Food and Drug Administration (FDA) 39, 40, 64, 66, 67, 68, 73, 74, 86, 89, 93, 110, 113, 125, 131, 150
- food hygiene
  - as research area 169, 171
  - Codex Committee on Food Hygiene 128, 129
  - consultants 130
  - criteria 113
  - end of chain control 112–14
  - European Directives 118
  - food microbiologists and 131
  - food microbiology and 52, 62
  - fragmentation of 14
  - large businesses and 199
  - liberalisation 198
  - local regimes 123
  - performance-based 139
  - promotion of industrial food hygiene 125
  - regulation of 1, 12, 201, 202
- food microbiology
  - co-word analysis of 63–4
  - elite of 131, 134, 169, 170, 173, 189, 202
  - food regulation and 202
  - industry support 64, 176
  - journals of 126
  - limits of 65
  - microbiology and 52

- professional jurisdiction of 131
- reorientation of 130
- food safety; *see also* risk assessment
  - food additives 2, 5, 46, 50–51, 60, 61, 62, 68, 69, 74, 147, 151, 159, 162, 176
  - food surveillance 12, 60, 65
  - food zoonoses 47
  - food-borne diseases 39, 136
  - White Paper on Food Safety 45
- functional foods 46, 144–7, 150, 152, 156, 158, 159, 162, 163, 212
- functional efficacy 144, 148
- Funtowicz, S. and Ravetz, J. 2
  
- Gabriel 99, 102–9, 172, 177, 178, 181, 182, 183, 190, 193, 194, 196
- General Agreement on Tariff and Trade (GATT) 70
- General Food Law 46, 47, 64, 70, 119, 144; *see also* European food law; European Food Safety Authority (EFSA)
- global knowledge network 19, 23; *see also* network concept
- Gold, Harry 56, 74
- guidance
  - as source 213
  - for HACCP 113, 114, 116, 125, 126, 128, 131
  - for PMM 142, 149, 156, 163, 164, 203
  - for PVP 83
  - generic guidance 120
  - inducement of change in industry 103
  - normative pyramid 150
  - risk management 99
  - soft law 18
  
- Haas, P. 20–21, 24–26
- Hazard Analysis Critical Control Point (HACCP)
  - audit and 120, 121
  - critical control points (CCP) 112, 115, 125, 131, 134–8
  - critical control points, determination of 127–8
  - critical failure areas concept and 124
  - decision-tree 75, 118, 126, 127, 129, 134
  - developing countries and 136, 209
  - HACCP-like approaches and systems 112, 113, 123, 139, 140
  - hazard analysis 115, 122, 123, 127, 136, 149
  - ISO and 116, 128, 138
  - local vs. central establishment of critical control points 121–3, 130
  - logic sequence 116, 117, 129, 134
  - manuals 35
  - negotiation of critical control points 123, 139
  - philosophy 121, 127
  - policy panacea 115
  - principles 112
  - quality assurance 120, 122, 130, 131, 132, 172, 180, 187, 201, 213
  - regulatory concept 12, 13, 14, 15
  - reliability 124, 199
  - risk analysis 199
  - systems thinking 124, 199
  - total quality management and 128
  - translation 136
- Heads of Agencies (HOA) 73, 95, 96, 107, 110
- Heads of Medicines Agencies (HMA): *see* heads of agencies (HOA)
- Hill, Bradford 56
  
- imputation, research programme of 12, 17, 37–8, 46–7, 52, 55–6, 60, 63–4, 71–2, 76, 202, 213; *see also* evaluation
- Inman, William 56, 67, 86
- inspectors
  - as actors of regulatory intervention 213
  - as consultants and auditors 121
  - as regulatory intermediaries 130
  - complexity of the role of 198, 199
  - food microbiologists and veterinarians as 202
  - HACCP plans and external inspectors 113, 120
  - National Advisory Committee on Microbiological Criteria for Foods (NACMCF) and 126
  - negotiation with 123, 139

- self-control and 119
- sharing of information with 9
- surveillance of food contaminations 7
  - training of food inspectors 125
- interest groups 24
- International Commission for the Microbiological Safety of Food (ICMSF) 69, 76, 125–9, 130, 131–5, 137, 139, 176, 177, 178, 181, 183, 186, 198, 201, 207
- International Conference of Harmonisation (ICH) 33, 77, 78, 79, 81, 83, 84, 88, 97–9, 101–5, 107–10, 167, 177, 178, 181, 193, 209; *see also* Council for the International Organization of the Medical Sciences (CIOMS)
- International Life Science Institute (ILSI) 126, 128, 129, 131, 132, 138, 142, 148, 149, 154–63, 165, 167, 178, 181–3, 206, 209, 210
- interstitial organisations 15, 34, 169, 181–6, 188, 189, 207, 208
- invisible college
  - as club 183, 189
  - benefits of using the notion of 11, 19, 31–4
  - big players and 139
  - embeddedness in regulation 103–4
  - frontiers 161–3, 204
  - HACCP principles and 114
  - history of the 29
  - junction between evaluation and standard-setting 11, 99, 108; *see also* evaluation
  - manufacturing of consensus 134
  - occupational diversity in 172
  - PMM experts as 159
  - scientometrics and 29–30
- Jasanoff, S. 2, 171
- Jean-Claude 132, 176–8, 186–8, 199
- John 158, 161, 163, 178, 187
- Joint Expert Committee for Food Additives (JECFA) 68, 69, 70, 178
- Kefauver, Senator Carey Estes 40
- Keohane, R. 21, 25
- Knorr-Cetina, K. 26, 27, 27
- Koch, Robert 52
- Lachance, Paul 124
- Lezaun, J. 7
- liability 17, 43, 56
- life-style medicines 86, 95
- Lipobay 43, 97, 110, 153; *see also* cerivastatin; drug withdrawal
- marketing authorisation
  - as a type of control 47
  - European Union procedures for 40–43
  - for food products 46, 68
  - for novel foods 149, 150, 152
  - of me-too drugs 86
  - phytosterol esters 153
  - positive list and 68
  - pre-marketing tests 13, 56, 145, 147, 195
  - revision of 87, 98
  - submission of risk management plan and 81
- Marks, H. 48, 66, 71, 73
- medicines agencies
  - blaming of 94
  - Medicines and Health products Regulatory Agency (MHRA) 73, 76; *see also* Medicines Control Agency (MCA)
  - Medicines Control Product Agency (MCA) 73, 86, 88, 89, 101, 107, 110, 167, 172, 177, 193, 206
  - organisation 82, 83, 156
- Merck 96, 97
- me-too medicine 5, 17, 84, 85, 86, 95
- Meyer, J. 192
- Michael 132, 140, 172, 176, 177, 178, 186, 199
- microbiology
  - as scientific discipline 176, 201
  - microbiological risk assessment 37, 65, 69, 199
- Ministry of Agriculture, Food and Fisheries (MAFF) 151, 152
- Modell, Walter 74
- Mogoutov, Andrei 214
- multi-professionalism: *see* scientists

- National Advisory Committee on Microbiological Criteria for Foods (NACMCF) 126, 129, 131, 132, 135
- National Aeronautics and Space Administration (NASA) 112, 124, 131, 186, 198, 199
- National Research Council (NRC) 3, 64, 70, 126, 166, 199
- Nestlé 126, 129, 132, 145, 176
- network concept
- embedded knowledge network 23
  - global knowledge network 19, 23
  - global public policy networks 22
  - network of professionals 20, 21, 24
  - transnational policy networks 22
- Nicolas 159, 161, 163, 175, 176, 178, 187, 189
- non-governmental organisations 20, 161, 210
- novel foods
- as regulatory domain 1
  - European novel food regulation 146, 147, 150, 153, 165, 166
  - experience of 15
  - pre-market regulation and 46, 68
  - post-market monitoring and 142, 158–66
  - regulatory definition 144–52
  - regulatory terminology 146
  - research interest 156
  - researchers in 169
  - side-effects of 8, 13, 14
- Olestra 154
- Organisation for Economic Cooperation and Development (OECD) 159, 161, 178
- Parmar, I. 23
- Pasteur, Louis 52
- Patrick 159, 161, 163, 176, 178, 190
- Paul 88, 89, 94, 99, 101, 102, 103, 105, 107, 108, 109, 172, 177, 178, 182, 187, 193, 196
- Periodic Safety Update Report (PSUR) 98, 99, 102, 195, 196
- pharmaceutical industry 41, 49, 67, 102, 179, 182, 207, 211
- pharmacoepidemiology 57, 67, 69, 74, 86, 89, 91, 196
- pharmacovigilance
- additional pharmacovigilance activities 80
  - audit 82, 87, 96, 196
  - centralised procedure and 40, 41
  - definition of 17
  - drug monitoring 57, 59, 73, 101
  - French school of pharmacovigilance 43
  - industrial pharmacovigilance 177, 194, 195, 197
  - national pharmacovigilance systems 42, 43, 67, 90, 108
  - pharmacovigilance responsible person 82, 102, 170, 172
  - public health and 86–8, 92, 93, 97, 98, 99, 103, 107, 196
  - regulatory philosophy 93
  - safety databases 35, 64, 65, 75, 83, 90, 194
  - terminology 102
- phase IV studies 43, 81
- phocomelia 42, 59, 90; *see also* adverse drug reaction
- phytosterol esters 152–5, 159, 163, 166
- Pillsbury 14, 112, 114, 124, 125, 126, 131, 139, 140, 186, 198, 199
- post-market monitoring (PMM)
- consumer targeting 155
  - dose exposure 153
  - exposure assessment guidance for 142–3
  - International Life Science Institute (ILSI) and 158–63
  - post-launch monitoring (PLM) and 152, 153, 154–5, 156, 157, 163
  - post-marketing surveillance (PMS) and 156, 157
  - reassurance 8, 148
  - regulatory concept 12, 13, 14, 15, 150–57
  - risk analysis principle 199–200
  - risk assessment 143–9, 153, 157, 158
  - scope 143, 148, 153, 164, 165, 202, 203
- policy enterprise 20, 24, 39
- Porter, T. 7, 18

- post-normal science 2
- practolol 55, 91
- Price, D. J. de S. 29–31, 34
- Procter & Gamble 154
- Prodi, Romano 45
- pharmaceutical risk management 83, 84, 96, 97, 194, 196
- blame avoidance and 94, 96, 99, 106
  - FDA risk management 95–6
- pharmacovigilance planning (PVP)
- agencies' reorganisation and 79, 82, 83
  - as research area 169
  - changes linked to the introduction of 79, 83
  - data requirements and 80
  - European Union guideline 81
  - ICH guideline 79, 80, 81
  - pre-/post-marketing division 82, 83
  - pharmaceutical companies' reorganisation and 83, 191
  - pharmacovigilance specification 12, 78, 79, 81, 88–90, 92, 94, 99, 101, 109, 193, 194
  - public health and 196
  - regulatory concept 12, 14, 77–9, 89, 90
  - risk management and 97, 98, 167
  - risk management plans 78, 79, 81, 103, 194
  - risk minimisation 77, 78, 81, 95, 106, 183
  - risk reduction 196
  - safety specification 80, 124, 203
- physicians
- hospital physicians 172, 173
  - physicians and national pharmacovigilance systems 53–6
  - physicians and reporting of adverse drug reactions 67, 69, 77, 82, 156, 205
- qualification, research programme of 12, 47–53; *see also* evaluation; imputation
- Quorn 151, 152
- Rank Hovis McDougall (RHM) 151
- Red Book 64
- regulatory agencies
- agencification 206
  - as nodal point of invisible colleges 205
  - as risk assessment agencies 6
  - circulation of scientists and 11
  - creation of the European Food Safety Authority 47
  - creation of the European Medicines Evaluation Agency 41
  - democratic record of regulatory agencies 209–10
  - sharing of information 9
- regulatory authority 157, 181
- regulatory concepts 1, 8, 10
- as typifications 5–7
  - conceptual power 17; *see also* Carpenter, D.
  - impact of 191–204
  - regulatory concepts as objects of research 178, 179
  - regulatory concepts as standards 11, 35, 189
- regulatory space 8, 29
- risk 1–8, 16, 75
- hazard 2, 46, 60, 63, 64, 65, 75
  - quantitative dose–response assessment 65
  - risk analysis as science 2, 3, 16, 17, 60, 64
  - risk analysis principle 45, 47, 70
  - risk assessment 2–6, 10, 12, 16, 17, 27, 45, 47, 61, 64–5, 70
  - risk assessment/risk management terminology 164
  - risk perception 3
- risk regulation
- approaches of 17
  - as set of activities of control 6–7
  - prioritising risks 3
  - regulatory failure 15, 84, 98, 192, 196, 197, 206, 207
  - regulatory rationalisation 212
  - risk regulation regimes 211
  - as systems of control 191, 193, 205, 206, 207
- Royal Society of London for the improvement of natural knowledge 29, 36

- Royer, René-Jean 58, 93, 105, 173, 174, 183
- Sanitary and Phytosanitary Measures (SPS) 70, 116, 129, 140
- Santer, Jacques 73, 74, 165
- Sauer, Fernand 73, 209
- scientific committee for food (SCF) 76, 153, 154, 158, 159, 163, 178
- scientific community, concepts of; *see also* epistemic community; invisible college  
 community of thought 20  
 core-sets 26, 27  
 research networks 26  
 scientific communities 5, 23, 24, 25, 27  
 thought collectives 25  
 trans-epistemic arenas 26
- scientific disciplines 20, 24, 32, 48  
 history of scientific disciplines 213
- experiments  
 industry experiments 1, 13, 30, 33, 142, 150, 158, 192, 203, 205  
 scientific experiments 48, 50, 52, 54, 56, 58, 64, 66, 71, 72
- scientists  
 accumulation of positions 143, 159, 171–2, 178, 180  
 disciplines and professionalisation of scientists 170, 171, 173, 174, 181  
 medical scientists 53, 99, 104, 105, 106, 107, 109, 163; *see also* drug safety scientists  
 multi-professionalism 11, 169, 191  
 physicians and 1, 7, 17, 33, 41, 42, 49  
 professional jurisdiction 168, 195, 196  
 professional rationalisation 175  
 professional trajectories of 31, 179  
 scientific elite 1, 11, 14, 19, 29, 32, 35, 39  
 social authority 11, 15, 20, 23, 27, 32, 34  
 training as physicians 172, 173
- scientisation 10  
 rationalisation and 192, 204, 212
- Scott, J. 5–7
- Selznick, P. 8, 17
- Slaughter, A.-M. 21
- Society for Risk Analysis (SRA) 16
- standardisation  
 as emergent action 204  
 boundaries of 158, 164  
 invisible colleges of 29–34  
 science-driven 10  
 standard-setting and 18
- standard-setting organisations  
 as sites of scientists' circulation 11, 176, 177  
 drug safety experts and 14, 99, 102, 109  
 International Life Science Institute (ILSI) as 161  
 New Approach and 119, 147
- statins 17, 84, 85, 86, 92, 93, 98, 153, 195
- Stockholm Centre for Organizational Research (SCORE) 10
- Stone, D. 23, 28
- thalidomide 39–42, 49, 54, 58, 59, 81, 87, 90, 91
- theorisation 13, 15  
 abstraction 13, 158, 201  
 lesson drawing 13, 89, 96, 107, 109  
 regulatory modelling 13, 112, 113, 138, 199, 200
- toxicology 12, 37, 48–52  
 allowable daily intake (ADI) 51, 74  
 dose-response and toxicology 61, 64, 65  
 food toxicology 50, 52, 64, 65, 68, 69  
 reference dose 69  
 relations with industry 64
- transboundary risk management 9
- transnational  
 transnational and the global 9  
 transnational policy networks 22; *see also* network concept  
 transnational regulation 10, 11, 19, 22, 123, 134, 181, 188, 208  
 transnational risk regulation 8, 167  
 transnationalisation of experts' career 177, 181, 188
- trans-science 2, 37
- Truhaut, René 51, 59, 68, 69, 74
- uncertainty 2, 3, 12, 20, 26, 27, 37, 48, 52, 54, 59, 64, 71



- Unilever 152–6, 158, 159, 163, 166, 187, 203
- Uppsala Monitoring Centre (UMC) 92, 101
- veterinarians 7, 51, 69, 121, 131, 136, 137, 201, 202
- vioxx 43, 96, 110
- Waller, Patrick 86, 88, 89, 99, 105, 107, 108, 172, 187, 195
- Weinberg, A. 2
- World Health Organization (WHO)  
contribution to pharmacovigilance planning 86, 89  
Council of International  
Organisation of Medical  
Sciences and 102, 182
- endorsement of HACCP 113, 114, 125, 186
- food safety department 136
- global food safety challenges 116
- International Commission for the  
Microbiological Safety of  
Foods and 129, 131, 132, 134, 135
- national pharmacovigilance systems  
and 42, 104, 107  
Patrick and 178
- quantitative dose-response  
assessment and 65
- risk analysis and 70
- World Trade Organization (WTO) 75, 113, 116
- Worsley, Benjamin 29



















